{
    "clinical_study": {
        "@rank": "151410", 
        "acronym": "CHAMPION 2", 
        "arm_group": {
            "arm_group_label": "Carfilzomib, Cyclophosphamide and Dexamethasone (CCd)", 
            "arm_group_type": "Experimental", 
            "description": "All subjects will be treated with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for 8 cycles. Each cycle will be repeated every 28 days."
        }, 
        "brief_summary": {
            "textblock": "This is a Phase 1b, multicenter, open-label dose-escalation study of twice-weekly\n      carfilzomib in combination with cyclophosphamide and dexamethasone (CCd) as initial therapy\n      for subjects with newly diagnosed multiple myeloma."
        }, 
        "brief_title": "A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Newly diagnosed multiple myeloma\n\n          2. Measurable disease, as defined by 1 or more of the following\n\n               -  Serum M-protein \u2265 0.5 g/dL, or\n\n               -  Urine M-protein \u2265 200 mg/24 hours, or\n\n               -  In subjects without detectable serum or urine M-protein, serum free light chain\n                  (SFLC) > 100 mg/L (involved light chain) and an abnormal kappa lambda ( \u03ba/\u03bb)\n                  ratio\n\n          3. Males and females \u2265 18 years of age\n\n          4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n\n          5. Adequate hepatic function\n\n          6. Left ventricular ejection fraction (LVEF) \u2265 40%\n\n          7. Absolute neutrophil count (ANC) \u2265 1.0 \u00d7 10E9/L\n\n          8. Platelet count \u2265 50 \u00d7 10E9/L\n\n          9. Calculated or measured creatinine clearance (CrCl) of \u2265 15 mL/min\n\n        Exclusion Criteria:\n\n          1. Planned autologous HSCT for the initial therapy of newly diagnosed multiple myeloma\n\n          2. Multiple myeloma of immunoglobulin M (IgM) subtype\n\n          3. Prior systemic treatment for multiple myeloma\n\n          4. Glucocorticoid therapy within 14 days prior to enrollment that equals or exceeds the\n             equivalent of dexamethasone 160 mg\n\n          5. Known amyloidosis\n\n          6. Active congestive heart failure (New York Heart Association [NYHA] Class III to IV),\n             symptomatic ischemia, or conduction abnormalities uncontrolled by conventional\n             intervention.  Myocardial infarction within 6 months prior to enrollment.\n\n          7. Known human immunodeficiency virus (HIV) seropositive, hepatitis C infection, and/or\n             hepatitis B (subjects with hepatitis B surface antigen [SAg] or core antibody\n             receiving and responding to antiviral therapy directed at hepatitis B are allowed)\n\n          8. Significant neuropathy (Grades \u2265 2) within 14 days prior to enrollment\n\n          9. Any other clinically significant medical disease or condition that, in the\n             investigator's opinion, may interfere with protocol adherence or a subject's ability\n             to give informed consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "27", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01980589", 
            "org_study_id": "2012-003"
        }, 
        "intervention": [
            {
                "arm_group_label": "Carfilzomib, Cyclophosphamide and Dexamethasone (CCd)", 
                "description": "Carfilzomib will be administered as a 30-minute intravenous (IV) infusion on Days 1, 2, 8, 9, 15, and 16. On Days 1 and 2 of Cycle 1, all subjects will receive carfilzomib at 20 mg/m2.", 
                "intervention_name": "Carfilzomib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "PR-171", 
                    "PR171", 
                    "Kyprolis\u00ae (carfilzomib) for Injection"
                ]
            }, 
            {
                "arm_group_label": "Carfilzomib, Cyclophosphamide and Dexamethasone (CCd)", 
                "description": "Cyclophosphamide will be administered orally (PO) at the dose of 300 mg/m2 on Days 1, 8, and 15.", 
                "intervention_name": "Cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Carfilzomib, Cyclophosphamide and Dexamethasone (CCd)", 
                "description": "Dexamethasone will be administered PO or IV at 40 mg on Days 1, 8, 15, and 22.", 
                "intervention_name": "Dexamethasone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Dexamethasone", 
                "Dexamethasone acetate", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "multiple myeloma", 
        "lastchanged_date": "June 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Anaheim", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "The Oncology Institute of Hope and Innovation"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Encinitas", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "California Cancer Associates for Research and Excellence"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "West Hollywood", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "James R. Berenson, MD, Inc."
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lafayette", 
                        "country": "United States", 
                        "state": "Indiana"
                    }, 
                    "name": "Horizon Oncology Research"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bethesda", 
                        "country": "United States", 
                        "state": "Maryland"
                    }, 
                    "name": "Center for Cancer and Blood Disorders"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Clinical Research Alliance"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }, 
                    "name": "Tennessee Oncology, PLLC"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Norfolk", 
                        "country": "United States", 
                        "state": "Virginia"
                    }, 
                    "name": "Virginia Oncology Associates"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects", 
        "overall_contact": {
            "email": "medinfo@onyx.com", 
            "last_name": "Onyx Medical Information", 
            "phone": "1-877-669-9121"
        }, 
        "overall_official": [
            {
                "affiliation": "Onyx Therapeutics, Inc.", 
                "last_name": "Priti Patel, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "James R. Berenson MD, Inc.", 
                "last_name": "James R. Berenson, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "US Oncology, Inc.", 
                "last_name": "Robert M. Rifkin, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Determine the maximum tolerated dose (MTD) of carfilzomib given twice weekly in combination with cyclophosphamide and dexamethasone (CCd) for subjects with newly diagnosed multiple myeloma. The MTD is defined as the highest carfilzomib dose at which fewer than 33% of subjects experience a treatment-related dose-limiting toxicity (DLT) during the first 28-day cycle.", 
            "measure": "Maximum tolerated dose (MTD)", 
            "safety_issue": "Yes", 
            "time_frame": "First cycle treatment over 28-days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01980589"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To estimate overall response rate (ORR) during CCd therapy. ORR is defined as the proportion of subjects with the best overall response of PR or better.", 
                "measure": "Overall Response Rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "10 months"
            }, 
            {
                "description": "To estimate time to response (TTR). TTR is defined as the time from the first dose of study treatment until the first evidence of a confirmed response of PR or better.", 
                "measure": "Time To Response (TTR)", 
                "safety_issue": "No", 
                "time_frame": "Up to 10 months"
            }, 
            {
                "description": "Safety and tolerability assessments will include extent of exposure to study treatment, AEs (including SAEs), laboratory values, vital sign results, and ECGs.", 
                "measure": "Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 10 months"
            }
        ], 
        "source": "Onyx Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Onyx Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}